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Introduction {#s1}
============

Proximal gastric cancer is defined as a tumor located in the upper 1/3 of the stomach [@pone.0108480-Japanese1]. According to JCGC 3^rd^ edition guideline [@pone.0108480-Japanese2], for advanced proximal gastric cancer, no.10 lymph node dissection (LND) should be involved in D2 lymphadenectomy with total or proximal gastrectomy. Since spleen-preserving no.10 LND (SPNo.10LND) does not significantly affect patient survival, morbidity and mortality rates when compared with no.10 LND plus splenectomy [@pone.0108480-Wanebo1]--[@pone.0108480-Nashimoto1], the former is increasingly adopted in patients with proximal gastric cancer. Obstacles to SPNo.10LND include deep location, splenic vascular variation, narrow anatomical space, proneness to capsular tearing and complicated adjacent structures. En bloc resection requires the spleen to be mobilized outside the abdominal cavity, along with the body and tail of the pancreas [@pone.0108480-Zhang1]. This procedure is not only technically difficult, but can increase postoperative complications such as spleen reversal, preventing SPNo.10LND from being a routine method. Laparoscopic methods can better delineate the perigastric fascia, intrafascial space, vasculature and other structures, enhancing the safety of lymphadenectomy in the splenic hilar area. However, only few centers could independently complete laparoscopic SPNo.10LND (LSPNo.10LND) [@pone.0108480-Hyung1]--[@pone.0108480-Hur1]. To date, LSPNo.10LND remains controversial for all advanced proximal gastric cancer, and there is no well-established predictive model for splenic hilar lymph node metastasis (SHLNM). This study was designed to formulate the optimal model for SHLNM and explore indications for LSPNo.10LND.

Methods {#s2}
=======

Patients {#s2a}
--------

The 346 patients involved in this study underwent LSPNo.10LND at the Department of Gastric Surgery of the Fujian Medical University Union Hospital from January 2010 to October 2013. Patient characteristics were recorded prospectively in our clinical database and used for a retrospective analysis in this study.

Patients were included if they 1) were preoperatively diagnosed with proximal gastric cancer by gastroscopic biospy; 2) had no distal metastasis on abdominal and pelvic computed tomography (CT) or on abdominal ultrasound, as well as no evidence of lesions in the perigastric organs and LNs around the abdominal aorta; and 3) had undergone D2 lymphadenectomy with pathological R0 resection.

Patients were excluded if 1) they had proximal gastric cancer intraoperatively diagnosed as T4b tumors; 2) distant metastases were detected before or during the operation; 3) they had preoperatively received neoadjuvant chemo- or radiotherapy; 4) detailed clinical information was lacking; or 5) they had a history of previous gastrectomy.

Of the 346 patients with proximal gastric cancer, 35 had SHLNM (metastasis group) and 311 did not (non-metastasis group). The 346 patients consisted of 267 males and 79 females, of mean age 61.4±10.6 years and with a mean tumor size of 54.74+25.25 mm. Forty-five patients (13.0%) were classified as stage I, 83 (24.0%) as stage II and 218 (63.0%) as stage III [@pone.0108480-Sobin1]. Tumor diameters were assessed as being located in the lesser curvature, greater curvature, anterior wall and posterior wall according to JCGC 3^rd^ edition guideline [@pone.0108480-Japanese2].

Surgical Procedures {#s2b}
-------------------

Depending on the tumor location, patients underwent laparoscopic assisted total gastrectomy (LATG) or laparoscopic assisted proximal gastrectomy (LAPG) with standard D2 lymphadenectomy. In brief, the procedure of LSPNo.10LND was performed as follow:

The patient is placed in the reverse Trendelenburg position with the head elevated approximately 15 to 20 degrees and tilted left side up at approximately 20 to 30 degrees. The surgeon stands between the patient's legs, with the assistant and camera operator both on the patient's right side.

First step-dissection of lymph nodes in the inferior pole region of the spleen: The assistant places the free omentum in the anterior gastric wall and uses his or her left hand to pull the gastrosplenicligament. The surgeon gently presses the tail of the pancreas and separates the greater omentum toward the splenic flexure of the colon along the superior border of the transverse mesocolon. Next, the anterior pancreatic fascia (APF) is peeled toward the superior border of the pancreatic tail, along the direction of the pancreas. Then, the peeled anterior lobe of the transverse mesocolon (ATM) and APF are completely lifted toward the cephalad, to expose fully the superior border of the pancreas and enter the retropancreatic space (RPS). The lower lobar vessels of the spleen (LLVSs) or lower pole vessels of the spleen can then be exposed. The assistant's right hand pulls up the lymphatic fatty tissue on the surface of the vessels, and the surgeon uses the non-functional face of the ultrasonic scalpel to dissect these lymphatic tissues, closing toward the vessels. The left gastroepiploic vessels (LGEVs) can then be revealed. Next, the assistant gently pulls the LGEVs, while the surgeon meticulously separates the fatty lymphatic tissue around them to denude them completely, then dividing them at their roots with vascular clamps. The division point is used as the starting point for the splenic hilar lymphadenectomy, to skeletonize one or two branches of the short gastric vessels (SGVs), which are divided at their roots toward the direction of the splenic hilum.

Second step-dissection of the lymph nodes in the region of the splenic artery trunk: The assistant places the free omentum between the inferior border of the liver and the anterior gastric wall and continually pulls the greater curvature of the fundus to the upper right, while the surgeon's left hand presses the body of the pancreas. The assistant's right hand pulls the isolated fatty lymphatic tissue on the surface of the splenic artery trunk. The surgeon denudes the middle of the splenic artery trunk until the crotch of the splenic lobar arteries lies along the latent anatomic spaces on the surface of the splenic vessels. The posterior gastric artery, which derives from the splenic artery, will always be encountered in this region; at this time, the assistant should clamp and pull the vessels upward, while surgeon denudes them and closes toward the splenic artery trunk. Then, the surgeon divides them at their roots with vascular clamps and completely dissected the fatty lymphatic tissue around the splenic vessels (No.11d).

Third step- dissection of lymph nodes in the superior pole region of the spleen: The assistant continually pulls the greater curvature of the fundus to the lower right, while the surgeon's left hand presses the vessels of the splenic hilum. Then, taking the division point of the LGEVs as the starting point, the assistant gently pulls up the fatty lymphatic tissue at the surface of the terminal branches of the splenic vessels and keeps it under tension, while the surgeon uses the non-functional face of the ultrasonic scalpel to cut the surface of the terminal branches of the splenic vessels, completely skeletonizing the vessels in the splenic hilum with meticulous sharp or blunt dissection. During the dissection process, two or three branches of the SGVs arise from the terminal branches of the splenic vessels and enter the GSL. At this time, the assistant should clamp and pull the vessels upward, while the surgeon meticulously dissects the surrounding fatty lymphatic tissue, closing toward the roots of the SGVs. Next, the surgeon divides the vessels at their roots with vascular clamps after confirming their destinations in the wall of the stomach. In particular, the last SGV in the superior pole region of the spleen is often very short and easy to damage, causing bleeding. At this time, the assistant should adequately pull the fundus to the lower right to expose the vessel completely and should assist in the careful separation of the surgeon. Then, the separation is continued to dissect completely the fatty lymphatic tissue in front of the splenic hilar. Dissection of the lymph nodes behind the splenic vessels can be performed when the tail of pancreas is located in the inferior border of the spleen, and it lies a certain distance from the splenic hilum. The assistant's left hand then ventrally lifts the termini of the splenic vessels using atraumatic grasping forceps, and the surgeon's left hand presses the Gerota's fascia. Then, the ultrasonic scalpel dissects the adipose tissue behind the splenic vessels in front of Gerota's fascia. Attention is required during this step so that the separation plane does not exceed Gerota's fascia, because doing so can damage the kidney, adrenal gland and related vessels or the nerves behind them. At this point, the splenic hilar lymphadenectomy is complete. An intraoperative view after splenic hilar lymphadenectomy is shown after the procedure. This procedure is what we call Huang\'s three-step maneuver for LSPNo.10LND. The results of this surgical technique are shown in [Figure S1](#pone.0108480.s001){ref-type="supplementary-material"}, [Figure S2](#pone.0108480.s002){ref-type="supplementary-material"}.

Ethics Statement {#s2c}
----------------

Ethics committee of Fujian medical union hospital approved this retrospective study. Written consent was given by the patients for their information to be stored in the hospital database and used for research.

Statistical analysis {#s2d}
--------------------

All the statistical analysis and graphics were performed with the SPSS 20.0 and the R project. Univariate analysis was operated to determine the risk factors. Binary Logistic Regression confirmed the independent risk factors. Akaike's information criterion (AIC) and the area under the ROC curve (AUC) were simultaneously evaluated the optimal predictive model of SHLNM. Through Stratification analysis and binary distribution test, we advocate the indication for LSPNo.10LND. All p value was lower than 0.05.

Results {#s3}
=======

1. Univariate analysis of risk factors for SHLNM {#s3a}
------------------------------------------------

The metastasis group consisted of 35 patients (10.1%) and the non-metastasis group of 311 patients (89.9%). None of early proximal gastric cancer in the metastasis group, compared with 35 of 311 (11.3%) had a advanced proximal gastric cancer s in the metastasis group. The average number of splenic hilar lymph nodes (SPHLNs) harvested was 2.69±2.76, 4.03±2.49 in the metastasis group and 2.56±2.80 in the non-metastasis group. [Table 1](#pone-0108480-t001){ref-type="table"} show the clinicopathological features of the various subgroups. SHLNM was significantly associated with tumor location (p\<0.001), tumor size (p\<0.001), CA-199 status, depth of invasion (p\<0.001), UICC N classification, and lymph node metastasis (LNM) at No.1--4, No.6--9, No.11 and No.12 LNs (p\<0.05 each), but not at No.5 LNs.

10.1371/journal.pone.0108480.t001

###### Clinicopathologic features of patients with and without SHLNM.
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                             SPHLN                                 
  ---------------------- ------------- ------------- ------------- ---------
  Age, yr                                                          
  ≤60                         155           137           18         0.405
  \>60                        191           174           17       
  Sex                                                              
  Male                        267           239           28         0.674
  Female                      79            72             7       
  BMI, kg/m^2^                                                     
  \<25                        302           273           29         0.407
  ≥25                         44            38             6       
  Histology                                                        
  undifferentiated            198           175           23         0.529
  mix                         66            60             6       
  differentiated              82            76             6       
  Location                                                         
  Lesser                      256           246           10        \<0.001
  Greater                     22            18             4       
  Anterior                     5             3             2       
  Posterior                   17            12             5       
  Circum                      46            32            14       
  Size (cm)                                                        
  \<5.5                       180           174            6        \<0.001
  ≥5.5                        166           137           29       
  LVI                                                              
  LVI(−)                      186           172           14         0.540
  LVI(+)                      160           139           21       
  CA199(U/mL)                                                      
  ≤37                         293           268           25         0.043
  \>37                        53            43            10       
  Surgery                                                          
  LAPG                         4             4             0         0.500
  LATG                        342           307           35       
  UICC(n)                                                          
  IA                          27            27             0        \<0.001
  IB                          18            18             0       
  IIA                         43            43             0       
  IIB                         40            40             0       
  IIIA                        47            45             2       
  IIIB                        71            66             5       
  IIIC                        100           72            28       
  Depth                                                            
  pT1                         35            35             0        \<0.001
  pT2                         26            26             0       
  pT3                         132           128            4       
  pT4                         153           122           31       
  LNM                                                              
  pN0                         87            87             0        \<0.001
  pN1                         51            50             1       
  pN2                         61            56             5       
  pN3                         147           118           29       
  Number of SPHLNs         2.69±2.76    2.56±±2.80     4.03±2.49     0.003
  Number of dissection    41.44±15.45   41.55±15.81   40.40±11.93    0.676
  No.1                      76(346)       63(311)       13(35)       0.022
  No.2                      79(346)       61(311)       18(35)      \<0.001
  No.3                     235(346)      202(311)       33(35)      \<0.001
  No.4                      81(346)       60(311)       21(35)      \<0.001
  No.5                      30(346)       24(311)        6(35)       0.074
  No.6                      48(346)       38(311)       10(35)       0.008
  No.7                     140(346)      112(311)       28(35)       0.001
  No.8                      54(346)       42(311)       12(35)       0.001
  No.9                      86(346)       69(311)       17(35)       0.001
  No.11                     60(346)       42(311)       18(35)      \<0.001
  No.12                     43(346)       34(311)        9(35)       0.012

Circum, includes more than 2 portions and circum patients; BMI, body mass index; LVI, lymphovascular invasion; LNM, lymph nodes metastasis.

No.1(Right cardial), No.2(Left cardial), No.3(LN along the lesser curvature ), No.4(LN along the greater curvature), No.5(Suprapyloric), No.6 (Infrapyloric), No.7(LN along the left gastric artery), No.8(LN along the common hepatic artery), No.9(LN along the celiac artery), No.11(LN along the splenic artery ), No.12(LN in the hepatoduodenal ligament ).

2. Multivariate analysis of risk factors for SHLNM {#s3b}
--------------------------------------------------

A binary logistic regression model evaluating 15 factors found that four were independent risk factors for SHLNM: depth of invasion, tumor location, metastasis status at No.7 LNs, and metastasis status at No.11 LNs ([Table 2](#pone-0108480-t002){ref-type="table"}). Compared with tumors located in the lesser curvature, those located in the greater curvature (OR 8.630), anterior wall (OR 42.265), posterior wall (OR 15.949), and circum (OR 9.678) had significantly higher risks of SHLNM (p\<0.05 each).

10.1371/journal.pone.0108480.t002

###### Binary logistic regression analysis of independent risk factors for SHLNM.
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  Variable                             OR     95%CI   p value  
  ---------- ---------------------- -------- ------- --------- -------
  Depth                                                        
                  T4a vs T2--3       5.921    1.786   19.628    0.004
  Location                                                      0.001
               Greater vs Lesser     8.630    1.942   38.352    0.005
               Anterior vs Lesser    42.265   2.516   710.016   0.009
              Posterior vs Lesser    15.949   3.583   71.003    0.001
                Circum vs Lesser     9.678    3.395   27.593    0.001
  No.7        positive vs negative   3.996    1.429   11.176    0.008
  No.11       positive vs negative   4.513    1.725   11.801    0.002

3. Comparisons of predictive models {#s3c}
-----------------------------------

To determine the optimal model for SHLNM, the area under the ROC curve (AUC) and the Akaike information criterion (AIC) were applied to various predictive models. The model that included tumor location, depth of invasion, and metastasis statuses at No.7 and No.11 LNs showed the highest accuracy (AUC 0.897, 95% CI0.851--0.944) and the lowest AIC score (−913.535; [Table 3](#pone-0108480-t003){ref-type="table"}, [Figure 1](#pone-0108480-g001){ref-type="fig"}).

![ROC curves assessing the accuracy of various predictive models.](pone.0108480.g001){#pone-0108480-g001}

10.1371/journal.pone.0108480.t003

###### Comparison of different predictive models for SHLNM.
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  Regression model    Lymph node status   AIC     AUC      95%CI(lower-upper)  
  ------------------ ------------------- ----- ---------- -------------------- --------------
  Depth                       −            −    −858.154         0.747          0.673--0.821
                             \+            −    −869.669         0.816          0.760--0.872
                              −           \+    −876.880         0.811          0.744--0.879
                             \+           \+    −881.525         0.845          0.792--0.898
  Location                    −            −    −869.265         0.763          0.671--0.855
                             \+            −    −890.473         0.842          0.766--0.918
                              −           \+    −901.094         0.839          0.766--0.913
                             \+           \+    −909.216         0.868          0.800--0.936
  Depth+Location              −            −    −886.955         0.844          0.781--0.906
                             \+            −    −898.971         0.883          0.830--0.935
                              −           \+    −908.990         0.884          0.833--0.936
                             \+           \+    −913.535         0.897          0.851--0.944
  No.7                       \+            −    −851.856         0.720          0.636--0.804
  No.11                       −           \+    −858.710         0.690          0.585--0.794
  No.7+No.11                 \+           \+    −869.092         0.775          0.689--0.861

4. Stratification analysis for SHLNM {#s3d}
------------------------------------

Because the incidence of SHLNM was much lower for tumors located in the lesser curvature than for the other four locations, the latter four were combined. None of the advanced proximal gastric cancer in the lesser curvature, without serosal invasion and without metastases at No.7 and No.11 LNs, were found to have SHLNM, as determined by stratification analysis and binary distribution tests based on the four independent risk factors of SHLNM (T2-3∶0/87, 95%CI 0.00--4.15). Accuracy analysis of confidence intervals (CI) for a binary distribution showed that, when the number of samples was close to 100, the smallest 95%CI ranged from 0.00 to 8.30, smaller than those observed previously, indicating an extremely low risk for SHLNM. In contrast, patients with tumors located in other portions of the stomach, without serosal invasion and without metastases at No.7 and No.11 LNs had a larger 95% CI, indicating that they had somewhat risk of SHLNM (n = 10, p = 0.05, L = 16) [@pone.0108480-Blyth1]. Moreover, changes in any of these factors enhanced the risks of SHLNM ([Table 4](#pone-0108480-t004){ref-type="table"}).

10.1371/journal.pone.0108480.t004

###### Stratification analysis of SHLNM for advanced proximal gastric cancer.
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  Location             No.7 & No.11    Depth     Ratio(%)        95%CI       Shortest CI length
  ------------------ ---------------- ------- -------------- -------------- --------------------
  Less                Non-metastasis   T2-3      0(0/87)       0.00--4.15           8.3
                      Non-metastasis    T4a     5.88(2/34)    0.72--19.68           14.4
                      Any-metastasis   T2-3     2.17(1/46)    0.00--11.53           11.2
                      Any-metastasis    T4a    11.29(7/62)    4.66--21.89           11.2
  Gre/Ant/Post/Cir    Non-metastasis   T2-3      0(0/15)      0.00--21.80            16
                      Non-metastasis    T4a    16.67(4/24)    4.74--37.38           14.4
                      Any-metastasis   T2-3      30(3/10)     6.67--65.25            16
                      Any-metastasis    T4a    54.55(18/33)   36.35--71.89          14.4

Gre, Greater curvature; Less, Lesser curvature; Ant, Anterior wall; Post, Posterior wall; Cir, Circum.

Discussion {#s4}
==========

As safety and feasibility were comfirmed, since 1994 the advent of lapascopic assisted gastrectomy (LAG) [@pone.0108480-Kitano1], it has been widely accepted. Compared with open surgery, LSPNo.10LND can more easily approach the deep portion and thoroughly dissect No.10 LNs without mobilizing the spleen [@pone.0108480-Hyung1]. Using a middle surgical approach, seven patients underwent this new technique in a single Japanese center, with a mean 2.6±2.8 No. 10 LNs retrieved [@pone.0108480-Okabe1]. In comparison, we retrieved a mean 2.69±2.76 No. 10 LNs, which was considerable with the conventional procedure [@pone.0108480-Schwarz1], suggesting that LSPNo.10LND is feasible in patients with advanced proximal gastric cancer.

We found that 35 of 346 patients (10.1%) with proximal gastric cancer and 35 of 311 patients (11.3%) with advanced proximal gastric cancer were positive for SHLNM, in agreement with previous findings [@pone.0108480-Sasada1]--[@pone.0108480-Csendes1]. According to JCGC 3rd edition guideline, for T1 group, there is no need to undergo No.10 LND. In our research, no SHLNM was found in this subgroup (0/35). Moreover, for T1 group, as the incidence of SHLNM was zero, there is no statistical meanings when a comparison made between it and others. So we only involved the T2--T4 groups in the multiple tests. The risk factors for SHLNM remain unclear. An analysis of 219 patients who underwent splenic hilar LN dissection found that the depth of invasion closely correlated with SHLNM. The likelihood of SHLNM in patients with AGC is increased in patients when tumors penetrating the subserosa or the muscularis with more than 7 macroscopic LN metastases [@pone.0108480-Yamamoto1]. In contrast with tumors located on the other portions, those located on the greater curvature were at higher risk for SHLNM (37.5%, 6/16) [@pone.0108480-Mnig1]. Regional LN metastasis was also related to SHLNM, especially in patients with proximal gastric cancer, with regional LN metastases always accompanied by metastases at No. 1, No. 3, and No.7 [@pone.0108480-Okajima1]. Deeper tumor invasion was associated with a higher risk for SHLNM. The probability of SHLNM was found to depend on primary tumor location. Tumors located in the greater curvature or posterior wall are more likely to spread through the LNs around the LGEVs, SGVs, and posterior gastric vessels (PGVs) to the No.10 LNs. The major lymphatic pathway of SHLNM was from No. 3 LN to No. 7 or No. 11 LN, finally No. 10 LN [@pone.0108480-Ikeguchi1]. Therefore, SHLNM was accompanied mostly by metastases at No. 7 and No. 11 LN, which was consistent with our multiple analysis. Except for other lymph nodes, only the metastases at No. 7 and No. 11 LN were correlated with SHLNM.

Although many studies have assessed the risk factors for SHLNM, none has formulated a predictive model. Multi-variable AUCs were utilized to evaluate the accuracy of the predictive models [@pone.0108480-Smeets1], while AIC was applied to assess the ability of different models to detect SHLNM [@pone.0108480-Ueno1]. By integrating AIC with AUC, we found that the optimal model for proximal gastric cancer included tumor location, depth of invasion, and metastasis status at No. 7 and No. 11 LNs.

Because of low risk for SHLNM, No.10LND was unnecessary for patients with early proximal gastric cancer. Our findings also demonstrate none of them diagnosed with SHLNM (0/35). However, the need for routine performance of NO.10LND in patients with advanced proximal gastric cancer remains unclear. Japanese guidelines recommend NO.10LND for all patients with advanced proximal gastric cancer [@pone.0108480-Japanese2]. One Japanese study, however, suggested that NO.10LND was unnecessary in patients with tumors located on the lesser curvature and without subserosal invasion, since survival rates were similar in patients who did and did not undergo NO.10LND [@pone.0108480-Sasada1]. A prospective study found that no patient with a stage IA, IB, II, or IIIA primary tumor was diagnosed with SHLNM, with NO.10LND not associated with long-term survival and postoperative morbidity rates [@pone.0108480-Csendes1]. Stratification analysis and binary distribution test were applied based on the independent risk factors involved in the optimal predictive model. The lymphatic pathway theory verified that tumors in the lesser curvature primarily invade from No.3 LN to No.7 or No.11 LN and from there to No.10 LN [@pone.0108480-Sasada1], [@pone.0108480-Ikeguchi1], [@pone.0108480-Aoyagi1]. As extremely low risk for SHLNM, when tumor locates in the lesser curvature without serosa invasion and metastasis to the No.7 and No.11 LN, this subgroup may avoid routine LSPNO.10LND. Whereas all other advanced proximal gastric cancer, with a higher risk of SHLNM, should undergo LSPNO.10LND.

Supporting Information {#s5}
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###### 

**Intraoperative view of laparoscopic spleen-preserving no. 10 lymph node dissection : Anterior view.** Abbreviations: SpA, splenic artery; SpV, splenic vein.

(TIF)

###### 

Click here for additional data file.

###### 

**Intraoperative view of laparoscopic spleen-preserving no. 10 lymph node dissection : Posterior view.** Abbreviations: SpV, splenic vein.

(TIF)

###### 

Click here for additional data file.
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